Do our aging cells necessitate that we age overall as people? Flipping it around, if we can stop or reverse enough cellular aging, will our overall aging be positively affected? It’s clear that people age very differently from each other and so do our cells and organs. Interestingly, intramurally in a sense the cells and […]
Weekly reads: aging cells, scientists relying on ChatGPT, anemone stem cells Read More »
What was the biggest upbeat regenerative medicine story of 2024? I have my own favorites but decided to run a poll. Just putting the poll together, it was evident that this year was unusually full of good and encouraging news. Diabetes and sickle cell regenerative medicine therapies In The Niche polling, so far Vertex Type
Positive regenerative medicine story of the year: diabetes & sickle cell were tops Read More »
The FDA recently warned Frontier Biologics, LLC, a Texas perinatal tissue manufacturer firm. Tallying the many FDA biologics warnings in 2024 It can sometimes feel like there are an uncountable number of unproven stem cell clinics However, the good news is that the FDA has been doing much more on this front in 2024. With
FDA warns Frontier Biologics as part of its more active trend Read More »
Remember former Trump’s FDA Commissioner Scott Gottlieb? Gottlieb’s back in the news in an interesting way related to the upcoming second Trump administration. I just wrote about what to expect from new FDA Commissioner nominee Marty Makary. In that piece, I noted that Scott Gottlieb first came to lead the FDA after a record of
Weekly reads: Scott Gottlieb v. RFK Jr., DNA typewriters, Arnold Caplan Read More »
How might Trump’s nominee to lead the FDA, Martin Makary, change the agency? Should we be worried or hopeful? I’ve been closely following the FDA and its commissioners ever since I started The Niche in 2010. I’ve been particularly interested in how these leaders impacted FDA actions on cell and gene therapies. How might Makaray
What you need to know about Martin Makary and planning for the Trump 2.0 FDA Read More »
What happens if unproven stem cell clinic firms like GIOSTAR start getting okays from the FDA to do clinical trials? On the one hand, it could reflect a positive trend of stem cell clinic firms working with the FDA and toward compliance. Having more robust data. However, I worry about some of these types of
It’s been a long saga for the FDA and the unproven stem cell clinic group called Cell Surgical Network, headquartered in Beverly Hills. A court case involving the two has been unfolding for many years. It has big implications for agency authority and the hundreds of stem cell clinics across the U.S. The case took
After a bit of a hiatus in 2024, our list of regenerative medicine and stem cell meetings returns for 2025. I’m noticing a lot of great stem cell meetings already scheduled for 2025. With the pandemic being less of an ever-present thing, most meetings are now only in-person these days. In a way, the hybrid
2025 regenerative medicine and stem cell meetings list Read More »
Is there a proven stem cell therapy for vision loss? When I started The Niche back in early 2010, one major area of hope was that there might one day be a stem cell therapy for vision loss or even blindness. Maybe even a cure for blindness. While we’re not there yet as a field,
What are the most significant stem cell and regenerative medicine good news stories of 2024? Since it has been an eventful year, there are many possibilities. Please see our poll at the bottom of this post and weigh in on what you think is the most important encouraging news. If you don’t see your choice
Poll on stem cell & regenerative medicine good news of 2024 Read More »